Patents Issued in August 12, 2008
  • Patent number: 7411050
    Abstract: Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: August 12, 2008
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson
  • Patent number: 7411051
    Abstract: The present invention relates to antibodies that specifically bind HDPPA04 polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said HDPPA04. Also encompassed by the invention are host cells and hybridomas for producing said antibodies. The invention further encompasses methods for detecting said HDPPA04 polypeptides using said antibodies.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: August 12, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben
  • Patent number: 7411052
    Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: August 12, 2008
    Assignee: Nuvelo, Inc.
    Inventor: Y. Tom Tang
  • Patent number: 7411053
    Abstract: Described herein are ligand-functionalized/azo compounds and methods of use thereof.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: August 12, 2008
    Inventors: Issifu I. Harruna, Guangchang Zhou
  • Patent number: 7411054
    Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: August 12, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Mark J. Williamson
  • Patent number: 7411055
    Abstract: The present disclosure provides attractin/mahogany-like polypeptides and fragments thereof, polynucleotides encoding such polypeptides and fragments, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides or fragments, and assays and methods employing these polypeptides, antibodies, and polynucleotides.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: August 12, 2008
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson
  • Patent number: 7411056
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: August 12, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Darrell C. Conklin, Julia E. Novak, Angela K. Hammond
  • Patent number: 7411057
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: August 12, 2008
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Douglas C Hanson, Mark J Neveu, Eileen E Mueller, Jeffrey H Hanke, Steven C Gilman, C. Geoffrey Davis, Jose R Corvalan
  • Patent number: 7411058
    Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: August 12, 2008
    Assignee: The University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Patricia W. Dowling, Julius S. Youngner
  • Patent number: 7411059
    Abstract: The present invention relates to a method for producing syringyl lignin in gymnosperms. The production of syringyl lignin in gymnosperms is accomplished by genetically transforming a gymnosperm genome, which does not normally contain genes which code for enzymes necessary for production of syringyl lignin, with DNA which codes for enzymes found in angiosperms associated with production of syringyl lignin. The expression of the inserted DNA is mediated using host promoter regions in the gymnosperm. In addition, genetic sequences which code for gymnosperm lignin anti-sense mRNA may be incorporated into the gymnosperm genome in order to suppress the formation of the less preferred forms of lignin in the gymnosperm such as guaiacyl lignin.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: August 12, 2008
    Assignee: Arborgen, LLC
    Inventors: Vincent L. Chiang, Daniel T. Carraway, Richard H. Smeltzer
  • Patent number: 7411060
    Abstract: The present invention relates to expression control sequences of a vertebrate liver fatty acid binding protein (L-FABP) gene that, when operably linked to a reporter (e.g., a heterologous reporter, such as the green fluorescent protein (GFP)), directly express the reporter in a fashion that mimics the liver-specific development of the L-FABP gene in the vertebrate.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: August 12, 2008
    Assignee: Academia Sinica
    Inventors: Jen-Leih Wu, Guor Mour Her
  • Patent number: 7411061
    Abstract: A method of synthesizing polynucleotides is disclosed. The method involves contacting a first nucleotide with a selected reactive group in the presence of an ionic liquid. The selected reactive group may be on a second nucleotide, a polynucleotide, or on a moiety on an insoluble substrate, for example in an oligonucleotide synthesizer.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: August 12, 2008
    Assignee: Agilent Technologies, Inc.
    Inventors: Joel Myerson, Michel G. M. Perbost, Douglas J. Dellinger, Geraldine F Dellinger
  • Patent number: 7411062
    Abstract: The present invention involves intermediates, including a 7?-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: August 12, 2008
  • Patent number: 7411063
    Abstract: The present invention describes the preparation of maytansinol by methods that minimize processing steps, and reduce solvent volumes, making the process more efficient, and scaleable. This process comprises a step of converting bridged acetals of maytansinol to maytansinol. The simplified processing also aids in lowering the potential for human exposure to chemicals. Also provided is an isolated C3 to C9 bridged acetal of maytansinol.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: August 12, 2008
    Assignee: Immunogen, Inc.
    Inventors: Wayne C. Widdison, Ravi V. J. Chari
  • Patent number: 7411064
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: August 12, 2008
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Hassan Mahmoud Elokdah, David Zenan Li
  • Patent number: 7411065
    Abstract: This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oglimers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: wherein E is nitrogen or C—R?; J is sulfur or oxygen; R?, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural ?-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases in the presence of thiol.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: August 12, 2008
    Assignee: Panagene, Inc.
    Inventors: Sung Kee Kim, Hyunil Lee, Jong Chan Lim, Hoon Choi, Jae Hoon Jeon, Sang Youl Ahn, Sung Hee Lee, Won Jun Yoon
  • Patent number: 7411066
    Abstract: Novel amino methylated 2-pyridinones, precursors, intermediates, and derivatives; the methods for the preparation of the same; uses of the same for inhibiting pili formation in bacteria; and pharmaceutical compositions comprising these compounds are described in this application. The present compounds may be employed to inhibit biofilm formation and thereby inhibit adherence of bacteria to a host cell.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: August 12, 2008
    Assignee: Washington University
    Inventors: Scott J. Hultgren, Jerome S. Pinkner, Fredrik Almqvist, Nils Pemberton, Veronica Aberg, Andreas Larsson
  • Patent number: 7411067
    Abstract: Provided are two novel crystalline forms of gatifloxacin, denominated form O and form V, and methods for their preparation.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: August 12, 2008
    Assignee: Teva Pharmaceutical Industries Ltd
    Inventors: Valerie Niddam-Hildesheim, Shlomit Wizel, Greta Sterimbaum, Ehud Amir
  • Patent number: 7411068
    Abstract: The invention provides reporter compounds based on squaric, croconic, and/or rhodizonic acid, among others, reactive intermediates used to synthesize the reporter compounds, and methods of synthesizing and using the reporter compounds, among others. The reporter compounds relate generally to the following structure Here, Z is a four, five, or six-member aromatic ring, and A, B, C, D, E, and F are substituents of Z, where F is absent when Z is a five-member ring, and where E and F are absent when Z is a four-member ring. A, B, C, D, E, and F are selected from a variety of elements and groups, including but not necessarily limited to O, S, Se, Te, N—Ra, C(Rb)(Rc), W1, and W2.
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: August 12, 2008
    Inventors: Ewald A. Terpetschnig, Anatoliy Tatarets, Olga Galkina, Iryna Fedyunyaeva, Leonid Patsenker
  • Patent number: 7411069
    Abstract: The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: August 12, 2008
    Assignee: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, James F. White, Michael Solomon
  • Patent number: 7411070
    Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: August 12, 2008
    Assignee: AstraZeneca AB
    Inventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Möller
  • Patent number: 7411071
    Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I): where X is S, O or N; Z is —T—COOR1 or —T—COR1; and T, R, R1, Ra, Rb, Rc, Rd, Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: August 12, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bingwei V. Yang, Lidia M. Doweyko, Arthur M. Doweyko
  • Patent number: 7411072
    Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: August 12, 2008
    Assignee: Eli Lilly and Company
    Inventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell
  • Patent number: 7411073
    Abstract: The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as novel non-steroidal selective glucocorticoid receptor modulators for treating a variety of autoimmune and inflammatory diseases or conditions, and possess advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity and/or metabolism. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: August 12, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Amjad Ali, Richard Beresis, Steven L. Colletti, Donald W. Graham, James R. Tata, Christopher F. Thompson
  • Patent number: 7411074
    Abstract: A process for preparing a compound of formula (I) where R4 and R5 are as defined in the specification; and R6 is hydrogen or a protecting group, which process comprises cyclisation of a compound of formula (II) where R4, R5 and R6 are as defined in relation to formula (I), and R7 is nitrogen-protecting group, and removing the group R7—, and thereafter if desired or necessary, removing any protecting group R6 to obtain the corresponding carboxylic acid. Novel intermediates and the use of the products in the preparation of pharmaceutical compounds is also described and claimed.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: August 12, 2008
    Assignee: AstraZeneca AB
    Inventors: Paul Murray, Jeremy Stephen Parker, Paul Schofield, Andrew Stocker
  • Patent number: 7411075
    Abstract: The present invention relates to atorvastatin calcium, a useful agent for lowering serum cholesterol levels. New atorvastatin calcium Form V, processes for preparing the new form, and pharmaceutical compositions and dosage forms containing the new form are disclosed.
    Type: Grant
    Filed: November 16, 2000
    Date of Patent: August 12, 2008
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Ari Ayalon, Michal Levinger, Sofia Roytblat, Valerie Niddam, Revital Lifshitz, Judith Aronhime
  • Patent number: 7411076
    Abstract: A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the following general formula (I): wherein X represents a single bond or a C1 to C6 alkylene group which may be substituted; A represents a C1 to C6 alkyl group which may be substituted, a C6 to C10 aryl group which may be substituted, or a 4 to 10-membered monocyclic or bicyclic and unsaturated, partly saturated, or completely saturated heterocyclic group which may be substituted, wherein said heterocyclic group comprises as ring-constituting atoms 1 to 4 hetero atoms selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: August 12, 2008
    Assignee: Institute of Medicinal Molecular Design, Inc.
    Inventors: Susumu Muto, Masayuki Komukai, Akiko Itai
  • Patent number: 7411077
    Abstract: A process for the preparation of citalopram and the pharmaceutically acceptable salts therof is disclosed by reacting 5-cyanophthalide with a 4-fluorophenyl magnesium halide, reducing the 3-hydroxymethyl-4-(4-fluorobenzoyl)benzonitrile with an agent reducing ketones to alcohols, submitting the thus-obtained 3-hydroxymethyl-4-[(4-fluorophenyl)hydroxymethyl)benzonitrile to a cyclization reaction to give 1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile without 1,1-bis(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile and treating 1,1-bis(4 fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile with a 3-(dimetylamino)propyl halide in the presence of a base.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: August 12, 2008
    Assignee: Adorken Technology SpA
    Inventors: Giovanni Cotticelli, Leone Dall'Asta, Gianluca Di Lernia
  • Patent number: 7411078
    Abstract: A method for producing furan-2,5-dicarboxylic acid (FDCA) is provided which can efficiently and quantitatively producing FDCA under mild conditions, without employing an expensive catalyst and with a reduced energy consumption. A furan ring compound having two functional groups selected from a hydroxymethyl group, a formyl group and a carboxyl group in the 2- and 5-positions of the furan ring, is oxidized with a metal permanganate in an alkaline environment to produce furan-2,5-dicarboxylic acid. Advantageously, the alkaline environment contains at least one of alkali metal hydroxides and alkali earth metal hydroxides, and the oxidation is performed at a temperature of from 1 to 50° C. by adding the permanganate metal salt to the alkaline aqueous solution containing the furan ring compound.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: August 12, 2008
    Assignee: Canon Kabushiki Kaisha
    Inventors: Toshinari Miura, Hirokazu Kakinuma, Takenobu Kawano, Hirohide Matsuhisa
  • Patent number: 7411079
    Abstract: A process for preparing a mixture of cetyl myristate and cetyl palmitate comprising reacting both myristic and palmitic acid with cetyl alcohol with an acid catalyst and one aromatic hydrocarbon at an elevated temperature and recovering from the aromatic hydrocarbon fraction the cetyl myristate and cetyl palmitate.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: August 12, 2008
    Assignee: Meracol Corporation Limited
    Inventors: Dianne Cadwallader, Parag Jhaveri
  • Patent number: 7411080
    Abstract: A basic copper salt selected from basic copper carbonate, basic copper sulfate, basic copper acetate, basic copper citrate, and basic copper nitrate is manufactured by contacting copper metal with an aqueous solution having ammonia; an acid selected from carbonic acid, sulfuric acid, acetic acid, nitric acid, or citric acid; and oxygen, under conditions where the copper metal is converted to the basic copper salt; and then recovering the basic copper salt. The most economical embodiment is where the ammonia is present in the aqueous solution is in an amount between about 6.7 g/l and about 15 g/l calculated as NH3, and the pH of the composition is between 8 and 10, and the temperature of the composition is between 25° C. and 100° C. The method is particularly useful if the basic copper salt is basic copper carbonate. The basic copper carbonate produced has the formula: (CuCO3)x(Cu(OH2)y, where y is 1 and x is between 0.1 to less than 1; or where y is 1 and x is 1, or where y is 1 and x is between 0.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: August 12, 2008
    Assignee: Phibro-Tech, Inc.
    Inventor: Gang Zhao
  • Patent number: 7411081
    Abstract: A process for preparing an organometallic framework material comprising reacting at least one metal salt with at least one at least bidentate compound capable of coordination to the metal ion of said metal salt, in the presence of an aqueous solvent system and at least one base wherein at least one bidentate compound comprises at least carboxy group and at least one further group which is not a carboxy group and which is capable of forming a hydrogen bridge linkage.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: August 12, 2008
    Assignees: BASF Aktiengesellschaft, The Regents of the University of Michigan
    Inventors: Ulrich Mueller, Gerald Lippert, Olga Schubert, Michael Hesse, Reinhard Hess, Michael Stoesser, Omar M. Yaghi
  • Patent number: 7411082
    Abstract: A catalyst for synthesis reaction that can allow the cross coupling reaction at an improved yield, and yet can be collected after used for the reaction and recycled, and a synthesizing method for a compound using the same catalyst for synthesis reaction.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: August 12, 2008
    Assignees: Cambridge University Technical Services Ltd., Daihatsu Motor Co., Ltd
    Inventors: Steven V. Ley, Martin D. Smith, Chandrashekar Ramarao, Antonia F. Stepan, Hirohisa Tanaka
  • Patent number: 7411083
    Abstract: The present invention relates generally to substituted acetic acid derivatives and methods of using them.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: August 12, 2008
    Assignee: Wyeth
    Inventors: Ariamala Gopalsamy, Scott Lee Kincaid
  • Patent number: 7411084
    Abstract: The present invention relates to a method of preparing a phenoxy alkanoic, alkenoic, or alkynoic acid or a salt thereof from a phenoxy containing compound via a dicarboxylate intermediate. The phenoxy alkanoic, alkenoic, and alkynoic acids and salts thereof prepared by this method are suitable for use in composition for delivering active agents via oral or other routes of administration to animals. Furthermore, the present invention relates to phenoxy dicarboxylic acids and their salts for delivering active agents, such as biologically or chemically active agents, to a target.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: August 12, 2008
    Assignee: Emisphere Technologies, Inc.
    Inventor: Joseph N. Bernadino
  • Patent number: 7411085
    Abstract: A carbon nanotube dispersion includes a carbon nanotube compound represented by structural formula A and a dispersion medium in which the carbon nanotube is dispersed or dissolved, wherein a moiety represented by double lines represents a carbon nanotube R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group having one or two carbon atoms, a substituted or unsubstituted aryl group or a substituted or unsubstituted carbodiimide group, R2 represents a substituted or unsubstituted alkyl group having from 1 to 4 carbon atoms, and m and n each independently represents an integer of 1 or more.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: August 12, 2008
    Assignee: Fuji Xerox Co., Ltd.
    Inventors: Masaki Hirakata, Taishi Shigematsu
  • Patent number: 7411086
    Abstract: The present invention is to provide a method of producing an N-alkylaminoalkyl (meth)acrylate containing a small amount of low boiling components, especially, containing a small amount of raw components, without any complicated operations or special apparatuses. The method of producing an N-alkylaminoalkyl (meth)acrylate comprising the steps of: (A) performing the reaction between the (meth)acrylic acid ester and the N-alkylaminoalkyl alcohol in a presence of a catalyst to obtain a reaction solution containing the N-alkylaminoalkyl (meth)acrylate; (B) distilling out components which have lower boiling points than the N-alkylaminoalkyl (meth)acrylate from the reaction solution obtained by the step (A); and (C) distilling the N-alkylaminoalkyl (meth)acrylate; and further comprising the step of: (D) adjusting water concentration at a range from 0.01 to 1 wt %. in the reaction solution which is located after the step (A) and before the step (C).
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: August 12, 2008
    Assignee: Dia-Nitrix Co., Ltd.
    Inventors: Shuhei Otsuka, Akira Ogawa, Tohru Endoh, Shingo Tanaka
  • Patent number: 7411087
    Abstract: The present invention provides a novel process for preparation of bisphosphonic acids or salts thereof, e.g. alendronic acid, by reacting a carboxylic acid, phosphorous acid and a halophosphorous compound in a water miscible neutral solvent.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: August 12, 2008
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Vijaykumar Muljibhai Patel, Trinadha Rao Chitturi, Rajamannar Thennati
  • Patent number: 7411088
    Abstract: There is provided stereoselective route to a compound of formula I: wherein R represents H or an alkali metal, Ar1 represents 4-chlorophenyl and Ar2 represents 2,5-difluorophenyl.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: August 12, 2008
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Ltd.
    Inventors: Karel Marie Joseph Brands, Sarah Elizabeth Brewer, Antony John Davies, Ulf H. Dolling, Deborah Camille Hammond, David Ross Lieberman, Jeremy Peter Scott
  • Patent number: 7411089
    Abstract: New nateglinide crystals, i.e. nateglinide A-type crystals (main peaks in powder X-ray diffraction: 4.4°, 5.2°, 15.7°, 18.5°(2?)), M-type crystals (main peaks in powder X-ray diffraction: 6.0°, 14.2°, 15.2°, 18.8°(2?)) and P-type crystals (main peaks in powder X-ray diffraction: 4.8°, 5.3°, 14.3°, 15.2°(2?)), can be produced by dissolving nateglinide in a solvent in which nateglinide is highly soluble and then adding a solvent in which nateglinide is difficultly soluble or, alternatively, by dissolving nateglinide in a mixed solvent composed of a solvent in which nateglinide is highly soluble and another solvent in which it is difficultly soluble, cooling the nateglinide solution to form crystals, filtering the mixture and drying the crystals at a specified temperature.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: August 12, 2008
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yoshihito Koguchi, Tomoko Nakao, Michito Sumikawa
  • Patent number: 7411090
    Abstract: The invention provides a process for the recovery of citric acid from an aqueous solution feed stream originating in fermentation of carbohydrates and utilizing an amine solvent extraction step for separation of impurities comprising: subjecting said aqueous solution feed stream A to a treatment for partial recovery of citric acid, wherein said treatment is other than amine solvent extraction, to form a first portion of purified citric acid B and a secondary feed stream F; subjecting at least a portion G of said secondary feed stream F to a treatment consisting of amine solvent extraction to form a second portion of purified citric acid solution and to reject substantial of impurities initially present in said portion of said secondary feed stream; subjecting said second portion of purified citric acid solution to crystallization; and recycling mother liquor from said crystallization.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: August 12, 2008
    Assignee: A.E. Staley Manufacturing Company
    Inventors: Avraham Baniel, Asher Vitner, David Gonen, David Heidel
  • Patent number: 7411091
    Abstract: This invention is related to compounds and use of N-Acyl-N?-benzyl-alkylendiamino derivatives of the following general formula (I), wherein A is a straight or branched C2-C8 alkyl chain; X is a methylene, oxygen, sulphur or a NR7 group; R1 is a straight or branched C1-C8 alkyl or C3-C8 alkenylene or C3-C8 alkynylene chain, optionally substituted with CF3, phenyl, phenoxy or naphthyl, the aromatic rings optionally substituted by one or more C1-C4 alkyl, halogens, trifluoromethyl, hydroxy or C1-C4 alkoxy groups; R2, R3 are independently hydrogen, a C1-C3 alkyl chain, halogen, trifluoromethyl, hydroxy or C1-C4 alkoxy groups; R4, R5 are independently hydrogen or C1-C6 alkyl; R6 is a hydrogen or a straight or branched C1-C8 alkyl or linked to R5 can form a five to seven membered lactam; R7 is hydrogen or C1-C6 alkyl; and the pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, in
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: August 12, 2008
    Assignee: Newron Pharmaceuticals S.p.A.
    Inventors: Florian Thaler, Cibele Maria Sabido David, Laura Faravelli, Stefania Gagliardi, Elena Colombo, Patricia Salvati
  • Patent number: 7411092
    Abstract: A quatemary ammonium salt of the following formula (1): {(R1)a(R2)b(R3)c(R4OCH2CH2OCH2CH2)dN}+.A???(1) [wherein, R1, R2 and R3 may be mutually the same or different and represent an alkyl group having 1 to 4 carbon atoms or analkyloxyethyl group of the formula (2): R5OCH2CH2—??(2) (wherein, R5 represents a methyl group or ethyl group), R4 represents a methyl group or ethyl group, and any two of R1, R2 and R3 may mutually bond at the end to form an alkylene chain, a, b and c represent an integer of 0 to 3, d represents an integer of 1 to 4, the sum of a, b and c is 3 or less, the sum of a, b, c and d is 4, and A? represents a bis(trifluoromethylsulfonyl)imidate ion [N(SO2CF3)2?], tetrafluoroborate ion (BF4?) or hexafluorophosphate ion (PF6?)].
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: August 12, 2008
    Assignee: Koei Chemical Company, Limited
    Inventors: Nobuaki Honma, Yoshimi Yamada
  • Patent number: 7411093
    Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: August 12, 2008
    Assignee: Hoffman-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Hans Peter Marty, Patrizio Mattei, Robert Narquizian
  • Patent number: 7411094
    Abstract: Process for preparing primary amines having a cyclopropyl unit and a primary amino group bound to an aliphatic or cycloaliphatic carbon atom (amine A) by cathodically reducing oximes having a cyclopropyl unit or oxime derivatives in which the hydrogen atom in the oxime group has been replaced by an alkyl or acyl group (oxime O) at a temperature of from 50 to 100° C. in an essentially anhydrous electrolyte solution in a divided electrolysis cell.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: August 12, 2008
    Assignee: BASF Aktiengesellschaft
    Inventors: Ulrich Griesbach, Harald Winsel, Hermann Putter
  • Patent number: 7411095
    Abstract: A method for producing highly pure enamines, which comprises reacting an aldehyde or ketone with an amine and treating the resulting reaction mixture with an acidic aqueous solution at a temperature between 0° C. and 30° C.
    Type: Grant
    Filed: January 18, 2005
    Date of Patent: August 12, 2008
    Assignee: Sankyo Company, Limited
    Inventors: Rei Okazaki, Shunshi Kojima, Hideharu Yokokawa
  • Patent number: 7411096
    Abstract: The present invention provides a process for producing an optically active phosphorus heterocyclic dimer including reacting, in the presence of a base, primary phosphine represented by formula (1) R—PH2 ??(1) is reacted with a compound represented by formula (2) Y—CnH2n—Y ??(2) in the presence of a base; the product is reacted with boron trihydride, oxygen, or sulfur to obtain a phosphorus heterocyclic compound represented by formula (3): the resultant compound is dimerized to produce a phosphorus heterocyclic dimer represented by formula (4): and then oxygen, sulfur, or borane is removed from the resultant phosphorus heterocyclic dimer to obtain an optically active phosphorus heterocyclic dimer represented by formula (5):
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: August 12, 2008
    Assignee: Nippon Chemical Industrial Co., Ltd.
    Inventors: Nobuhiko Oohara, Tsuneo Imamoto
  • Patent number: 7411097
    Abstract: By resolving objections in the prior art, provided are a novel copolymer suitable as a coating polymers which is excellent in adhesion to a substrate and can be used suitably as the polymer for the coating film having durability against pattern collapse in the finer pattern formation for progressed lithography technology and a method for producing the copolymer, as well as a novel thiol compound useful as a chain transfer agent in the production of the copolymer. The novel thiol compound of the present invention has the structure represented by the formula (1); wherein R1 is a bivalent substituent selected from linear, branched or cyclic saturated hydrocarbon having 1 to 15 carbon atoms.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: August 12, 2008
    Assignee: Maruzen Petrochemical Co. Ltd.
    Inventors: Takanori Yamagishi, Takahito Mita
  • Patent number: 7411098
    Abstract: The present invention relates to a process for preparing tetrahydrogeranylacetone (tetrahydropseudoionone) by aldol condensation of citral with acetone and subsequent hydrogenation. The invention further relates to the use of thus obtained tetrahydro-geranylacetone for preparing phytol, isophytol, tocopherol and/or tocopherol derivatives. In addition, the invention relates to processes for preparing tocopherols and/or tocopherol derivatives.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: August 12, 2008
    Assignee: BASF SE
    Inventors: Walter Dobler, Nicolaus Bahr, Alois Kindler, Christian Miller, Axel Salden
  • Patent number: 7411099
    Abstract: The present invention provides a liquid phase oxidation of toluene by using catalyst containing manganese (Manganese II acetate) in presence of Lewis acid (Stannous (II) chloride) and a bromide promoter (NaBr), at a temperature of 120° C. and at a pressure of air in the range of 70-400 psig, in presence of carboxylic acid (acetic acid), as a solvent, to obtain high selectivity to benzaldehyde (76%). High activity was obtained with minimum byproducts such as benzoic acid, benzyl alcohol and benzyl acetate.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: August 12, 2008
    Assignee: Council of Scientific & Industrial Research
    Inventors: Raghunath Vitthal Chaudhari, Kalpendra Baburao Rajurkar, Sunil Sopana Tonde, Vilas Hari Rane